ONI BioPharma Appoints New Chief Operational Officer
02 July 2008 - 6:32AM
Marketwired
ALACHUA, FL , a biopharmaceutical company, today announced that
David B. Hirsch has been appointed to Chief Operating Officer and
Chief Financial Officer to succeed Dorothy Delfino, who is retiring
from the Company. Mr. Hirsch began working for the company as a
consultant in April of this year and joined the Company as a
full-time employee in May. Ms. Delfino will remain with the Company
on a consultant basis.
Prior to joining ONI BioPharma, Mr. Hirsch operated a boutique
legal and consulting practice with a focus on financing and
advising emerging technology companies. Prior to starting his own
firm, he was a Manager in the Restructuring Group at Deloitte and
Touche, LLP in San Francisco, California and an associate at a The
Cottonwood Group, a venture capital firm in San Mateo, California.
He holds a MSIA (MBA) from the Tepper School of Business at
Carnegie Mellon University, a JD from Drake University Law School
and a BA in Economics from Indiana University. Mr. Hirsch is also a
licensed attorney in Florida and Indiana.
Mr. Stanley Stein, the Company's President and Chief Executive
Officer stated, "We are certainly excited about having David join
us. His breadth of experience in marketing, operations and finance
will be very valuable to ONI BioPharma."
About ONI BioPharma Inc.
ONI BioPharma Inc. (Oragenics, Inc. d/b/a/ ONI BioPharma, Inc.)
is a biopharmaceutical company with a pipeline of unique
proprietary technologies, some of which are being commercialized.
The Company also has a number of products in discovery, preclinical
and clinical development, with a concentration in the main
therapeutic area of infectious diseases, diagnostics, and oral
health. The Company has developed platform technologies with
respect to its products, thereby creating a pipeline of future
products, which the Company expects to develop.
Safe Harbor Statement: Under the Private Securities Litigation
Reform Act of 1995: This release includes forward-looking
statements that reflect ONI BioPharma's current views with respect
to future events and financial performance. These forward-looking
statements are based on management's beliefs and assumptions and
information currently available. The words "believe," "expect,"
"anticipate," "intend," "estimate," "project" and similar
expressions that do not relate solely to historical matters
identify forward-looking statements. Investors should be cautious
in relying on forward-looking statements because they are subject
to a variety of risks, uncertainties, and other factors that could
cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are
not limited to those set forth in our most recently filed annual
report on Form 10-K and quarterly report on Form 10-Q, and other
factors detailed from time to time in filings with the Securities
and Exchange Commission. We expressly disclaim any responsibility
to update forward-looking statements.
Contact: ONI BioPharma, Inc. Stanley B. Stein 386-418-4018 X222
www.oragenics.com
Oragenics (AMEX:ONI)
Historical Stock Chart
From May 2024 to Jun 2024
Oragenics (AMEX:ONI)
Historical Stock Chart
From Jun 2023 to Jun 2024